trending Market Intelligence /marketintelligence/en/news-insights/trending/WuRSy7GJv36tHjdDRuNmQg2 content esgSubNav
In This List

Abcam completes €120M acquisition of businesses from Expedeon

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Abcam completes €120M acquisition of businesses from Expedeon

Abcam PLC has completed its acquisition of the proteomics and immunology businesses of Expedeon AG.

Abcam CEO Alan Hirzel said acquiring the German biotechnology company adds its product and technology portfolio to Abcam's antibody research and tools.

In November, Cambridge, England-based Abcam announced its intent to acquire Expedeon's three proteomics and immunology businesses — Expedeon Ltd., Innova Biosciences Ltd. and TGR BioSciences— for €120 million in cash.

In January 2019, Abcam bought antibodies developer Calico Biolabs Inc. to expand its production capabilities.